Publications by authors named "E R Cancado"
Recurrence of Primary Sclerosing Cholangitis and De Novo Cholangiocarcinoma After Liver Transplantation: Results From the Brazilian Cholestasis Consortium.
Clin Transplant
October 2024
Background And Aim: Primary sclerosing cholangitis (PSC) has been shown to recur after liver transplantation (LT). Some studies have identified certain clinical and laboratory variables associated with an increased risk for recurrent PSC (rPSC) in Caucasians. Furthermore, de novo cholangiocarcinoma (CCA) has been reported anecdotally in patients with rPSC.
View Article and Find Full Text PDFAlkaline phosphatase and liver fibrosis at diagnosis are associated with deep response to ursodeoxycholic acid in primary biliary cholangitis.
Clin Res Hepatol Gastroenterol
October 2024
Objective: Primary biliary cholangitis is a chronic and progressive autoimmune liver disease, whose prognosis can be improved by normalizing alkaline phosphatase and bilirubin. While ursodeoxycholic acid (UDCA) is first line standard of care, approximately 40 % of patients exhibit incomplete response. We aimed to identify prognostic markers for deep response to UDCA therapy at presentation.
View Article and Find Full Text PDFArticle Synopsis
- Wilson disease (WD) is a rare illness where the body has too much copper, which can harm organs.
- The study looked at 262 patients to understand how they were diagnosed and how they responded to treatments, finding issues mostly in the liver and brain.
- Early diagnosis is tough, but doctors should consider WD sooner for young people with certain symptoms, and alternative treatments should be included in care plans.
A new and simple score to predict adequate and deep response to ursodeoxycholic acid in patients with primary biliary cholangitis: the ALP-A score.
Eur J Gastroenterol Hepatol
May 2024
Background: Ursodeoxycholic acid (UDCA) is the standard treatment for primary biliary cholangitis (PBC), but a significant proportion of patients do not respond adequately, leading to increased risk of adverse outcomes. This study aims to develop a new and straightforward predictive score to identify PBC patients likely to achieve a complete response to UDCA.
Methods: A logistic regression analysis was conducted using a derivation cohort of PBC patients to identify pre-treatment variables associated with response to UDCA.
Article Synopsis
- * Among the 123 AMA-positive AIH patients studied, 5.1% had AMA, more commonly found in females; however, there were no significant differences in liver damage or treatment response compared to AMA-negative patients.
- * The presence of AMA is noteworthy mainly when linked to non-specific bile duct injury, as these patients have a higher risk of progressing to cirrhosis and developing further liver damage over time, emphasizing the need for thorough liver biopsy assessments.